OOIR: Observatory of International Research

Papers

(The H4-Index of Drug Development Research is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Androgen sensitivity gateway to COVID‐19 disease severity	118
Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID‐19	69
Potential antiviral activity of isorhamnetin against SARS‐CoV‐2 spike pseudotyped virus in vitro	48
Epigallocatechin gallate and theaflavin gallate interaction in SARS‐CoV‐2 spike‐protein central channel with reference to the hydroxychloroquine interaction: Bioinformatics and molecular do	43
Surface receptor‐mediated targeted drug delivery systems for enhanced cancer treatment: A state‐of‐the‐art review	41
Challenges of peptide and protein drug delivery by oral route: Current strategies to improve the bioavailability	40
Synthesis, biological evaluation, and in silico study of novel library sulfonates containing quinazolin‐4(3H)‐one derivatives as potential aldose reductase inhibitors	39
Role of mineralocorticoid receptor antagonists in kidney diseases	37
The current drug discovery landscape for trypanosomiasis and leishmaniasis: Challenges and strategies to identify drug targets	37
Evaluation of hyaluronic acid nanoparticle embedded chitosan–gelatin hydrogels for antibiotic release	32
Prospects of multitarget drug designing strategies by linking molecular docking and molecular dynamics to explore the protein–ligand recognition process	31
Revisiting potential druggable targets against SARS‐CoV‐2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review	28
A comprehensive review of computational techniques for the prediction of drug side effects	27
Medicinal chemistry of anthranilic acid derivatives: A mini review	26
Snake venom‐derived bradykinin‐potentiating peptides: A promising therapy for COVID‐19?	25
Paeoniflorin inhibited nod‐like receptor protein‐3 inflammasome and NF‐κB‐mediated inflammatory reactions in diabetic foot ulcer by inhibiting the chemokine receptor CXCR2	25
COVID‐19 transmission through host cell directed network of GPCR	24
Bergenin inhibits bladder cancer progression via activating the PPARγ/PTEN/Akt signal pathway	23
Neuroprotective mechanisms of mangiferin in neurodegenerative diseases	23
Review of registered clinical trials for the treatment of COVID‐19	22
Smoking and COVID‐19: Similar bronchial ACE2 and TMPRSS2 expression and higher TMPRSS4 expression in current versus never smokers	22
CB2 receptor‐selective agonists as candidates for targeting infection, inflammation, and immunity in SARS‐CoV‐2 infections	21
Hybrid molecules based on 1,3,5‐triazine as potential therapeutics: A focused review	21
Osteoarthritis: Prognosis and emerging therapeutic approach for disease management	21
Estradiol reduces ACE2 and TMPRSS2 mRNA levels in A549 human lung epithelial cells	21

A new exploration toward adamantane derivatives as potential anti‐MDR agents: Design, synthesis, antimicrobial, and radiosterilization activity as potential topoisomerase IV and DNA gyrase inhibitors	21
Targeting cyclooxygenase enzyme for the adjuvant COVID‐19 therapy	21
Ginsenoside Rg3 attenuates ovariectomy‐induced osteoporosis via AMPK/mTOR signaling pathway	21